Research
Hormonal
Tirzepatide (5-15 mg weekly) produces dose-dependent weight loss (up to 11% in diabetics) and superior weight reduction compared to Semaglutide 1mg in patients with type 2 diabetes.
Tirzepatide is a weekly injection for type 2 diabetes that also causes significant weight loss (up to 11% in trials). It works by mimicking two gut hormones (GIP and GLP-1). It has been shown to reduce weight more than Semaglutide 1mg in diabetic patients.
StrongSupportsVERY_HIGH confidence
Contemporaneamente, è stato dimostrato un effetto dose dipendente sul peso corporeo, determinando un decremento ponderale pari al 7,9, 9,3 e 11% del peso corporeo, rispettivamente con il dosaggio di tirzepatide 5 mg, 10 mg e 15 mg rispetto al placebo (-0,9%)... le riduzioni medie del peso corporeo con tirzepatide alla dose di 5 mg, 10 mg e 15 mg sono state rispettivamente di -7,6 kg, -9,3 kg e -11,2 kg, rispetto a -5,7 kg ottenuti con semaglutide 1 mg
Why this rating
Based on Phase 3 SURPASS trials.
Source
Terapia farmacologica dell’obesità: attualità e prospettive future
Federica Vinciguerra et al. · L Endocrinologo · 2022
narrative_reviewCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →